Skip to content
DataLookout
Menu

OCARINA 3NCT07667322

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis

StatusActive, Not Recruiting
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 16 words
    • Primary completion date changed from estimate of Feb 15, 2028 to Sep 1, 2026
  2. Minor Enrollment closed, study ongoing
    • Site details revised at 12 of 12 sites
    v2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants With Adverse Events (AEs)
Timeframe: Up to 168 weeks

Secondary (3)

Ocrelizumab Serum Concentration at Specified Timepoints Following Single SC Administration
Number of Participants With Treatment-emergent Anti-drug Antibodies (ADAs) to Ocrelizumab
Number of Participants With Treatment-emergent ADAs to rHuPH20

Arms and interventions

Ocrelizumab SCExperimental

Participants will receive single ascending doses of ocrelizumab SC, co-formulated with recombinant human hyaluronidase (rHuPH20) on Day 1 of the 24 week dose-escalation phase. Participants who opt to continue treatment in the dose continuation phase will receive ocrelizumab SC at a dose determined in the dose escalation phase, every 24 weeks (Q24W) for 144 weeks.

Drugs: Ocrelizumab Co-formulated With rHuPH20

Sites

12 sites in 4 countries

United States 6, Brazil 2, Mexico 2, United Kingdom 2